Melatonin for Sleep After Ischemic Stroke
Melatonin can be considered as a reasonable treatment option for sleep disturbances after ischemic stroke, though it is not specifically endorsed in stroke guidelines and evidence remains limited to small studies showing modest benefits in this population.
Current Guideline Status
The available stroke guidelines do not provide specific recommendations for melatonin use in post-stroke sleep disorders. The 2021 AHA/ASA nursing care statement acknowledges that sleep disorders are common after stroke (prevalence 13.2%-94.0%) and emphasizes the importance of identifying and treating them, as they contribute to poststroke fatigue and affect recovery 1. However, no stroke-specific guidelines explicitly recommend melatonin for this indication.
Evidence from Sleep Medicine Guidelines
Melatonin has established efficacy in other contexts. The 2023 AASM guideline for REM sleep behavior disorder conditionally recommends immediate-release melatonin, typically starting at 3 mg at bedtime and titrating up to 15 mg as needed 2. The 2015 AASM guideline notes that melatonin is generally safe with few serious adverse effects at doses ≤10 mg daily, though concerns exist about purity and reliability of over-the-counter formulations 3.
Stroke-Specific Research Evidence
Two small studies specifically examined melatonin in post-stroke patients with positive results:
A 2015 Russian study of 60 post-stroke patients with insomnia found that 21 days of melatonin treatment significantly reduced daytime sleepiness (ESS scores: 5.7 vs 10, p<0.05), decreased sleep latency (17.8 vs 20.5 minutes, p<0.05), and reduced microactivations (15 vs 18, p<0.05) compared to controls 4
A 2000 Polish study of 30 post-stroke patients with sleep-wake rhythm disorders reported good results with melatonin for sleep initiation and continuity when prior psychotropic medications had failed 5
Safety Considerations in Stroke Patients
Important caveats for stroke patients specifically:
Glucose metabolism: Melatonin has been associated with impaired glucose tolerance in healthy women 3, which is particularly relevant given that many stroke patients have diabetes or metabolic syndrome
Drug interactions: Exercise caution in patients taking warfarin (common after cardioembolic stroke) and in those with epilepsy (which can complicate stroke) 3
Blood pressure effects: Both hypotension and hypertension have been reported 3, requiring monitoring in stroke patients with already compromised cerebrovascular autoregulation
Depression: Melatonin may increase depressive symptoms 3, and post-stroke depression affects approximately one-third of patients 6
Practical Recommendations
If prescribing melatonin for post-stroke sleep disturbances:
- Start with immediate-release melatonin 3 mg at bedtime (prolonged-release formulations lack sufficient evidence 2)
- Titrate in 3 mg increments up to 9-15 mg if needed for effect
- Use U.S. Pharmacopeia Verified formulations to ensure reliable dosing 3, 2
- Monitor for side effects including headaches, gastrointestinal upset, and mood changes
- Assess for and treat underlying contributors: sleep apnea (present in 38-40% of stroke patients 7), depression, pain, and medication effects
- Consider that benefits may persist for several days after discontinuation but gradually reemerge over weeks 2
Clinical Context
Sleep disorders after stroke are multifactorial, involving sleep apnea, nighttime disturbances, and excessive daytime sleepiness 1. Before initiating melatonin, evaluate for:
- Obstructive sleep apnea (which should be treated with CPAP per 7)
- Post-stroke depression (affects ~33% of patients 6)
- Medications causing sleep disruption
- Pain and other medical complications
The evidence supports melatonin as a low-risk intervention for post-stroke insomnia, particularly for sleep initiation difficulties, though it should not replace evaluation and treatment of other treatable sleep disorders common after stroke.